<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[GENMAB - En kur mod knoglemarvkræft anes i horisonten]]></title><description><![CDATA[<p dir="auto">"That was 15 years ago. Davis has already survived three times longer than patients with even the best prognosis could have expected in the 20th century. The father of a son and two daughters when he was diagnosed, he has been able to watch those children grow up, take in a foster son, who is now 11, and see his first grandchild born.</p>
<p dir="auto">And Davis is now part of a clinical trial of a targeted monoclonal antibody, daratumumab, that researchers hope will be a game changer in the treatment of myeloma. Even more amazing, Davis' story is becoming more and more common".</p>
<p dir="auto">Læs mere her: <a href="http://www.curetoday.com/publications/cure/2015/hematology-2015/inching-toward-a-cure-for-multiple-myeloma/1" rel="nofollow ugc">http://www.curetoday.com/publications/cure/2015/hematology-2015/inching-toward-a-cure-for-multiple-myeloma/1</a></p>
]]></description><link>https://dev.proinvestor.com/forum/topic/438981/genmab-en-kur-mod-knoglemarvkrft-anes-i-horisonten</link><generator>RSS for Node</generator><lastBuildDate>Wed, 22 Jul 2026 06:31:57 GMT</lastBuildDate><atom:link href="https://dev.proinvestor.com/forum/topic/438981.rss" rel="self" type="application/rss+xml"/><pubDate>Thu, 08 Oct 2015 02:33:42 GMT</pubDate><ttl>60</ttl></channel></rss>